Alyeska Investment Group L.P. Trims Stake in Ascendis Pharma A/S $ASND

Alyeska Investment Group L.P. lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 72.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,416 shares of the biotechnology company’s stock after selling 112,584 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.07% of Ascendis Pharma A/S worth $6,611,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth about $28,000. Brooklyn Investment Group boosted its position in Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 273 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $174,000. Dearborn Partners LLC purchased a new stake in shares of Ascendis Pharma A/S in the first quarter valued at approximately $203,000. Finally, New Wave Wealth Advisors LLC purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth approximately $222,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ASND shares. Royal Bank Of Canada upped their price target on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. UBS Group reiterated a “buy” rating and issued a $307.00 price objective (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Morgan Stanley began coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 price objective on the stock. Bank of America upped their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wedbush upped their price target on Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus target price of $244.36.

Ascendis Pharma A/S Trading Up 3.9%

Ascendis Pharma A/S stock opened at $205.91 on Friday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $207.00. The stock’s fifty day simple moving average is $182.68 and its 200-day simple moving average is $167.87. The firm has a market capitalization of $12.60 billion, a P/E ratio of -39.91 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.